Featured Press Releases

Regulus Therapeutics Progresses to Cohort 4 in Phase 1b MAD Trial of RGLS8429 for ADPKD Treatment

Regulus Therapeutics Progresses to Cohort 4 in Phase 1b MAD Trial of RGLS8429 for ADPKD Treatment

Made Scientific and Sentinel BioTherapeutics Announce a Strategic Manufacturing Partnership to Advance the Phase I/II Allogeneic ePP Encapsulated Cell Therapy Program

Made Scientific and Sentinel BioTherapeutics Announce a Strategic Manufacturing Partnership to Advance the Phase I/II Allogeneic ePP Encapsulated Cell Therapy Program

  • 15 Jul 2025

Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing...

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

XOCOVA® Becomes First Oral Option for Post-Exposure COVID-19 Prevention

XOCOVA® Becomes First Oral Option for Post-Exposure COVID-19 Prevention

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

  • PHC Corporation
  • 08 Sep 2026
Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

  • Release Versions
  • 07 Sep 2026
New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

  • SQ Innovation
  • 02 Sep 2026
Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

  • Jarrow Formulas
  • 02 Sep 2026
Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

  • Abbott
  • 01 Sep 2026
Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

  • Karyopharm Therapeutics Inc.
  • 31 Aug 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.